New study aims to predict best pancreatic cancer therapy

NCT ID NCT07326150

Ongoing Knowledge-focused Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This observational study of 70 pancreatic cancer patients aims to build a model that predicts how well a patient will respond to chemoprevention combined with targeted therapy. Researchers will analyze tumor tissue and blood samples using advanced techniques like spatial transcriptomics. The goal is to create a tool that personalizes treatment decisions for better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a tool that helps doctors predict which pancreatic cancer treatments will work best for each patient.
What could go wrong: This is a small, early-stage observational study, not a treatment trial. The model may not prove accurate enough for real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER NON-RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER NON-RESECTABLE PANCREATIC CANCER RESECTABLE

Contacts and locations

Locations

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

Zhejiang, Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.